Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas

APMIS

Volumn 117, Issue 9, 2009, Pages 651-659

  Bozkurt, Suheyla Uyar ^a   Ayan, Erdogan ^b   Bolukbasi, Fatihhan ^b   Elmaci, Ilhan ^b   Pamir, Necmettin ^c   Sav, Aydin ^c  

^a MARMARA UNIVERSITY   (Turkey)

^b GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Meningioma; MIB 1 index; Osteonectin; P53; Recurrence; SPARC

Indexed keywords

KI 67 ANTIGEN; OSTEONECTIN; PROTEIN P53;

ADULT; ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SURVIVAL RATE; TUMOR RECURRENCE;

CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; OSTEONECTIN; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 69449106610     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02516.x     Document Type: Article

References (41)

1. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, IL : Central Brain Tumor Registry of the United States, 2005.
2. Perry A. Meningiomas. In : Mclendon RBD, Rosenblum M, Brunder JM editors. Russell& Rubinstein's Pathology of Tumors of the Nervous System, 7th edn. London : Edward Arnold Ltd, 2006 : 427 474.
3. Louis DN OH, Wiestler O, Cavenee WK, editors. WHO Classification of the Central Nervous System. Lyon : IARC Press, 2007 : 164 172.
4. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997 94 : 14719 14724.
5. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. 'Malignancy' in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999 85 : 2046 2056.
6. Sweetwyne MT, Brekken RA, Workman G, Bradshaw AD, Carbon J, Siadak AW, et al. Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem 2004 52 : 723 733.
7. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol 1999 31 : 1363 1366.
8. Menon PM, Gutierrez JA, Rempel SA. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol 2000 17 : 683 693.
9. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999 30 : 339 344.
10. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995 64 : 70 5.
11. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003 63 : 5376 5380.
12. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, et al. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999 189 : 46 52.
13. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997 108 : 210 214.
14. Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 2000 78 : 336 341.
15. Sakai N, Baba M, Nagasima Y, Kato Y, Hirai K, Kondo K, et al. SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol 2001 32 : 1064 1070. (Pubitemid 33015666)
16. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000 6 : 1140 1149.
17. Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004 91 : 1924 1930.
18. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001 166 : 2495 2499.
19. Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003 97 : 2412 2419.
20. Strojnik T, Zidanik B, Kos J, Lah TT. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery 2001 48 : 598 605.
21. Perry A, Chicoine MR, Filiput E, Miller JP, Cross DT. Clinicopathologic assessment and grading of embolized meningiomas: a correlative study of 64 patients. Cancer 2001 92 : 701 711.
22. Cho H, Ha SY, Park SH, Park K, Chae YS. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci 1999 14 : 199 205.
23. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994 8 : 163 173.
24. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001 19 : 816 827.
25. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999 47 : 1495 1506.
26. Holland PW, Harper SJ, McVey JH, Hogan BL. In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol 1987 105 : 473 482.
27. Sage H, Vernon RB, Decker J, Funk S, Iruela-Arispe ML. Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 1989 37 : 819 829. (Pubitemid 19156464)
28. Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999 5 : 237 241.
29. Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A. Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol 2006 32 : 525 531.
30. Amatya VJ, Takeshima Y, Sugiyama K, Kurusi K, Nishisaka T, Fukuhara T, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001 32 : 970 975.
31. Lane TF, Iruela-Arispe ML, Sage EH. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J Biol Chem 1992 267 : 16736 16745.
32. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008 11 : 231 246.
33. Tremble PM, Lane TF, Sage EH, Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 1993 121 : 1433 1444.
34. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernojovsky T, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997 3 : 171 176.
35. Gilles C, Bassuk JA, Pulyaeva H, Sage H, Foidart JM, Thompson EW. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998 58 : 5529 5536.
36. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008 27 : 691 705.
37. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003 22 : 5021 5030.
38. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001 159 : 609 622.
39. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage H. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003 111 : 487 495.
40. Said N, Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005 167 : 1739 1752.
41. Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 2006 118 : 310 316.